Research programme: histone deacetylase inhibitors - Merck & Co.
Latest Information Update: 29 Aug 2011
At a glance
- Originator Merck & Co
- Class Small molecules
- Mechanism of Action Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 29 Aug 2011 No development reported - Preclinical for HIV infections in USA (unspecified route)
- 13 Mar 2007 Preclinical trials in HIV infections in USA (unspecified route)